Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

This study is testing a new CAR-T cell therapy called anitocabtagene autoleucel as a first-line treatment for newly diagnosed multiple myeloma (a cancer of plasma cells in the bone marrow). CAR-T therapy involves engineering a patient's own immune cells to attack cancer cells. The study tests different patient groups based on age and transplant eligibility. **You may be eligible if...** - You are 18 or older, newly diagnosed with multiple myeloma - You have measurable disease on standard lab tests - Your general health score (ECOG) is 0 or 1 - You have adequate heart, kidney, and liver function - For one group (Cohort A): you are 70 or younger; for other groups: 80 or younger **You may NOT be eligible if...** - You have already received treatment for multiple myeloma (except the induction regimen specified) - You have severe heart disease or significantly reduced heart function - You have uncontrolled infections or serious fluid around the lungs - You are pregnant or breastfeeding - You have had a prior stroke or serious bleeding within the past year Talk to your doctor to see if this trial is right for you.